Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)WXIBF -3.45%94 Forward Rate of Return (Yacktman) % is 19.61% as of Dec. 2025, which is 3% above its 10-year median of 18.98. GuruFocus rates WXIBF with a GF Score™ of 94/100 and a GF Value™ of $5.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 178 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 77.53% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. WuXi Biologics (Cayman)'s forward rate of return for was 19.61%.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % or its related term are showing as below:
WXIBF'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 14.9 Med: 18.98 Max: 19.76
Current: 19.65
During the past 12 years, WuXi Biologics (Cayman)'s highest Forward Rate of Return was 19.76. The lowest was 14.90. And the median was 18.98.
WXIBF's Forward Rate of Return (Yacktman) % is ranked better than 77.53% of 178
companies
in the Biotechnology industry
Industry Median: 1.7
vs WXIBF: 19.65
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
WuXi Biologics (Cayman) Forward Rate of Return (Yacktman) % Related Terms
WuXi Biologics (Cayman) Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Forward Rate of Return (Yacktman) % Chart
WXIBF vs VRTX, REGN, MRNA: Forward Rate of Return (Yacktman) % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Forward Rate of Return (Yacktman) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % falls into.
WuXi Biologics (Cayman) Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 19.61% mean?
WuXi Biologics (Cayman) (WXIBF) has a Forward Rate of Return (Yacktman) % of 19.61% as of Dec. 2025. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on WuXi Biologics (Cayman) and its competitors. This is near median its historical median of 18.98. Over the past decade, WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % has ranged from 14.90 to 19.76. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #40 out of 178 companies in the Biotechnology industry, placing it in the top 22.5%.
Is WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % too high?
WuXi Biologics (Cayman)'s current Forward Rate of Return (Yacktman) % of 19.61% is near median its 10-year median of 18.98. Over the past 10 years, this metric has ranged from a low of 14.90 to a high of 19.76. The Biotechnology industry median Forward Rate of Return (Yacktman) % is 1.70. WuXi Biologics (Cayman)'s value of 19.61% is 1053.5% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #40 out of 178 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Forward Rate of Return (Yacktman) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #40 out of 178 companies for Forward Rate of Return (Yacktman) %. This places WuXi Biologics (Cayman) in the top 23% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 1.70. WuXi Biologics (Cayman)'s value of 19.61% is 1053.5% above this benchmark. Historically, WuXi Biologics (Cayman)'s own Forward Rate of Return (Yacktman) % has ranged from 14.90 to 19.76 over the past decade. While the company's 10-year median is 18.98 vs. the industry median of 1.70, WuXi Biologics (Cayman) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Biotechnology company?
The median Forward Rate of Return (Yacktman) % among Biotechnology companies is 1.70, based on 178 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Forward Rate of Return (Yacktman) % of 19.61% is 1053.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Forward Rate of Return (Yacktman) % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Forward Rate of Return (Yacktman) % is 19.61%, which is near median its own 10-year median of 18.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.41, compared to a current price of $6.01 — trading 11.1% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 19.61%, which is near median its 10-year median of 18.98 and 1053.5% above the Biotechnology industry median of 1.70. WuXi Biologics (Cayman)'s overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Forward Rate of Return (Yacktman) % is 19.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of $6.01 is trading 11.1% above its estimated GF Value™ of $5.41.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.
Key valuation signals for WXIBF:
Forward Rate of Return (Yacktman) %: 19.61% (near median its 10-year median of 18.98)
GF Value™: $5.41 vs. price of $6.01 (11.1% above fair value)
Industry Position: 1053.5% above the Biotechnology median (#40 of 178)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics (Cayman) Inc. is a global contract research, development, and manufacturing organization (CRDMO) focused on biologics. Incorporated in 2014 as a spin-off from WuXi PharmaTech, it provides end-to-end services spanning drug discovery, cell line development, clinical and commercial manufacturing, and formulation of antibodies, bispecifics, antibody-drug conjugates, and other biologics. The company operates through integrated platforms including WuXiBody and its multiple "biologics foundry" manufacturing facilities across China, Ireland, Germany, and the United States. Its customers are pharmaceutical and biotechnology companies worldwide, ranging from startups to large multinationals. Revenue is generated primarily through fee-for-service contracts tied to project milestones and commercial manufacturing agreements, with a significant portion derived from North American and European clients. WuXi Biologics competes with other large biologics CDMOs such as Lonza, Samsung Biologics, and Fujifilm Diosynth.
94GF Score
Get the complete analysis for WXIBF
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
